Regeneron halting higher doses in fasinumab trials

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said an IDMC recommended discontinuing two higher dose regimens of osteoarthritis (OA) and pain candidate fasinumab. Regeneron

Read the full 219 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE